Literature DB >> 9798753

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

M Filippi1, M Rovaris, R Capra, C Gasperini, T A Yousry, M P Sormani, F Prandini, M A Horsfield, V Martinelli, S Bastianello, I Kühne, C Pozzilli, G Comi.   

Abstract

In this study we assessed the safety, efficacy and cost-effectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected for clinical trials. The number of enhancing lesions, the number of new enhancing lesions and the number of active scans were used to evaluate the sensitivity of the contrast-enhanced MRI to disease activity. The dose of Gd, and the effect of introducing a delay between the contrast injection and the scan were both appraised. Every 4 weeks for 3 months, and in two separate sessions, scans were obtained from 40 patients with relapsing-remitting or secondary progressive multiple sclerosis, 5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg) or triple dose (0.3 mmol/kg) Gd injection. There were 435 enhancing lesions (242 of which were new) on the early standard dose scans, 479 (263 new) on the delayed standard dose, 772 (365 new) on the early triple dose and 827 (404 new) on the delayed triple dose. There were 109 scans revealing active disease on the early standard dose scans, 112 on the delayed standard dose, 119 on the early triple dose and 120 on the delayed triple dose. Statistical simulations indicated that the sample sizes needed for both cross-over and parallel-group trials with similar powers are lower if serial monthly triple dose MRI is used. No side-effects were reported and no significant changes in blood test parameters were found throughout the study. This study shows that the serial use of triple dose Gd is safe, and that it increases the sensitivity of serial monthly enhanced MRI in detecting multiple sclerosis activity significantly. Its use should enable preliminary trials of experimental therapies for multiple sclerosis to be conducted in small patient populations, over a short period of time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798753     DOI: 10.1093/brain/121.10.2011

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

1.  Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.

Authors:  J A Koziol; S Wagner; D F Sobel; L S Slivka; J S Romine; J C Sipe; H P Adams
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

Review 2.  Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.

Authors:  Massimo Filippi; Maria A Rocca; Marco Rovaris
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Authors:  R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

4.  Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.

Authors:  Francesco Sardanelli; Andrea Iozzelli; Caterina Losacco; Alessandra Murialdo; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

Review 5.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

6.  Safety of the long-time monthly triple dose of a Gd-based contrast agent.

Authors:  Francesco Sardanelli; Gianluigi Mancardi; Massimo Filippi
Journal:  Eur Radiol       Date:  2003-03-26       Impact factor: 5.315

Review 7.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

Review 8.  MR imaging in multiple sclerosis: review and recommendations for current practice.

Authors:  K-O Lövblad; N Anzalone; A Dörfler; M Essig; B Hurwitz; L Kappos; S-K Lee; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-17       Impact factor: 3.825

Review 9.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

10.  Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't.

Authors:  Ilana R Leppert; S Narayanan; D Araújo; P S Giacomini; Y Lapierre; D L Arnold; G B Pike
Journal:  J Neurol       Date:  2014-02-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.